Detalhe da pesquisa
1.
Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Gastroenterology
; 148(2): 355-366.e1, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25311593
2.
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Gastroenterology
; 147(1): 132-142.e4, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24704719
3.
Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders.
Antimicrob Agents Chemother
; 58(2): 1136-45, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24295986
4.
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Antimicrob Agents Chemother
; 58(6): 3429-36, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24709256
5.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23811112
6.
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial.
Hepatology
; 57(6): 2155-63, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504636
7.
A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin.
Liver Int
; 34(10): 1550-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24329937
8.
Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.
J Hepatol
; 57(1): 39-46, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22414766
9.
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C.
J Infect Dis
; 204(4): 601-8, 2011 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21791662
10.
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study.
J Hepatol
; 54(6): 1130-6, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21145848
11.
Education by a nurse increases response of patients with chronic hepatitis C to therapy with peginterferon-α2a and ribavirin.
Clin Gastroenterol Hepatol
; 9(9): 781-5, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21683161
12.
Does Epoetin Beta Still Have a Place in Peginterferon Alpha-2a Plus Ribavirin Treatment Strategies for Chronic Hepatitis C?
J Interferon Cytokine Res
; 36(3): 204-14, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26700738
13.
Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Clin Res Hepatol Gastroenterol
; 39(4): 443-50, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25636238
14.
Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.
AIDS
; 18(13): F21-5, 2004 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-15316334
15.
Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.
Antivir Ther
; 18(8): 1015-9, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23558093
16.
Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C.
Antivir Ther
; 18(7): 885-93, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23804631
17.
Sustained virological response after 14-day treatment with danoprevir and 48-week treatment with pegylated interferon-α2a (40 KD) plus ribavirin.
Antivir Ther
; 17(5): 927-32, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22611092